Method of determining favorable prognosis against progressing fr

Details Method of determining favorable prognosis against progressing fr Method of determining favorable prognosis against progressing fr

1997-12-22

1999-08-24

Stucker, Jeffrey

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

4241881, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 514 19, G01N 3353, A61K 3921, A61K 3800

Patent

active

059424010

ABSTRACT:
The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.

REFERENCES:
patent: 5336758 (1994-08-01), Berzofsky et al.
patent: 5439809 (1995-08-01), Haynes et al.
M. R. Klein, F. Miedema, Trends in Microbiology 3, 386 (1995).
I. P. M. Keet. et al, AIDS 7, 51 (1993).
B. F Haynes, G. Pantaleo, A.S. Fauci, Science 271, 324 (1996).
D. F. Nixon et al., Nature 336, 484 (1988).
B. D. Walker et al, Science 240, 64 (1988).
F. Buseyne et al., J. Virol. 67. 694 (1993).
Y. Riviere et al, J. Virol. 63, 2270 (1989).
R. A. Koup et al, Blood 73, 1909 (1989).
R. P. Johnson, B.D. Walker, Curr. Top. Microbiol. Immunol. 189, 35 (1994).
S. Lamhamedi-Cherradi et al, AIDS 6, 1249 (1992).
S. Lamhamedi-Cherradi et al, AIDS 9, 421 (1995).
Y. Riviere, M. N. Robertson, F. Buseyne, Curr. Top Microbiol. Immunol. 189, 65 (1994).
C. Rinaldo et al. J. Virol 69, 5838 (1995).
A. Carmichael, X. Jin, P Sissons, I Borysiewicz, J. Exp. Med. 177, 249 (1993).
R. A. Koup et al., Journal of Virology 68, 4650 (1994).
M. R. Klein et al, J. Exp. Med. 181, 1365 (1995).
A M. Geretti et al, J. Inf. Dis. 174, 34 (1996).
J. W. Mellors, et al, Science 272, 1167 (1996).
S. Jurriaans, et al, Virol. 204, 223 (1994); E. Hogervorst, et al, J. Infect. Disc. 171, 811 (1995); J.W. Mellors, et al, Ann. Intern. Med. 122, 573 (1995); D.R. Henrard, et al, JAMA 274, 554 (1995); K. Sasela, S.E. Stevens, P. Rubinstein, P.E. Taylor, D. Baltimore, Ann. of Intern. Med. 123, 641 (1995).
C. A. van Baalen, et al, AIDS 7, 781 (1993).
B. Culmann-Penciolelli et al, J Virol. 69, 618 (1995).
B. Culmann et al, Eur. J. Immunol. 19, 2382 (1989).
T. Seshamma, O. Bagasra, D. Trono, D. Baltimore, R. J. Pomerantz, Proc. Natl. Acad.
J. Embretson et al. Nature 359 (1993).
T. Hope, R. J. Pomerantz, Curr Top Microbiol. Immunol. 193, 91 (1995).
A. Ranki, A. Lagerstedt, V. Ovod, E. Aavik, K. J. Krohn, Arch Virol. 139, 365 (1994).
V. Blazevic, A. Ranki, K. J. E. Krohn, AIDS Res. Hum. Retroviruses 11, 1335 (1995).
R. M. Zinkernagel, A. Althage, J. Exp. Med. 145, 644 (1977).
Ulmer et al., (1993) Curr. Opinion Invest. Drugs. 2 (9): 983-989.
Hope T., Pomerantz R.J., Current topics in Microbiology and Immunology 193:91-105.
Gayner R.B 1995, Current Topics in Microbiology and Immunology 193:51-77.
Moss B., Science, vol. 252, pp. 1662-1667 (Jun., 1991).
D. Baxby et al., Vaccine vol. 10, Issue 1, 1992.
E. Gonczol et al, Vaccine, vol. 13, No. 12, pp. 1080-1085, 1995.
Jean-Lue Imler, Vaccine vol. 13, No. 13, pp. 1143-1151, 1995.
M.B. Sztein et al., The Journal of Immunology, 1995, 155: pp. 3987-3993.
A. Aldovini et al., Nature (1991), vol. 351: 479-482.
J.W. Shiver et al., Annals New York Academy of Sciences, pp. 198-208.
S.K. Chai et al, The Journal of Immunology, vol. 149:2385-2390, No. 7, Oct. 1, 1992.
J.P. Sauzet et al., Vaccine, Vo.. 13, No. 14, pp. 1339-1345, 1995.
F. Zhou et al., The Journal Immunology, vol. 149, 1599-1604, No. 5, Sep. 1, 1992.
H. Takahashi et al., Nature, vol. 344:873-875, Apr. 26, 1990.
Voge et al., Vaccine Design, Ed. Powell et al, 1995, chapter 7, pp. 141-228.
A. Moore et al., Vaccine, vol. 13, No. 18, pp. 1741-1749, 1995.
Sally E. Adams, Vaccine Research, vol. 2: 163-172, No. 3, 1993.
Choppin et al., HLA-Binding Regions of HIV-1 Proteins, The Journal of Immunology, vol. 147, pp. 575-583, No. 2, see Table 1 and 2, p. 5761, Jul. 1991.

Affiliated with

Also associated with

Rating

Method of determining favorable prognosis against progressing fr does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of determining favorable prognosis against progressing fr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining favorable prognosis against progressing fr will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-465566